Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma

Anticancer Research

Volumn 18, Issue 6 A, 1998, Pages 4355-4361

  Savas, Burhan ^a,b   Kerr, Pauline E ^a   Ustun, Kasan ^b   Cole, Susan P C ^a   Pross, Hugh F ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Chemotherapy,; Interleukin 2; Multidrug resistance protein; P glycoprotein; Small cell lung carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CHROMIUM 51; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; LYMPHOKINE ACTIVATED KILLER CELL; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR CELL LINE;

CARCINOMA, SMALL CELL; CELL SURVIVAL; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, MULTIPLE; HUMANS; K562 CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG NEOPLASMS; LYMPHOCYTES; P-GLYCOPROTEIN; REFERENCE VALUES; TUMOR CELLS, CULTURED;

EID: 0032429984     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Diggs CH, Engeler JE, Prendergast EJ, Kramer K: Small cell carcinoma of the lung. Cancer 69: 2075-2083, 1992.
2. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989.
3. O'Brien ML, Tew KD: Glutathione and related enzymes in multidrug resistance. European J Cancer 32A(6): 967-78, 1996.
4. Jain N, Lam Y-M, Pym J, Campling BG: Mechanisms of resistance of human small cell lung cancer lines selected in VP- 16 and cisplatin. Cancer 77(9): 1797-1808, 1996.
5. Bradley G, Juranka PF, Ling V: Mechanism of multidrug resistance. Biochim.Biophys. Acta 948: 87-128, 1988.
6. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
7. Izquerdo UA, Scheffer GL, Flens MJ, Schroijer AB, van der Valk P, Scheper RJ: Major vault protein LRP-related multidrug resistance. Eur J Cancer 32A(6): 979-984, 1996.
8. Kartner N, Ling V: Multidrug resistance in cancer. Sci. Am. 260: 44-51, 1989.
9. Hamada H, Tsuruo T: Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P- 81Ycoprotein) as90ciated with multidrug resistance in K562/ADM cells. Cancer Res 48: 4926-4932, 1988.
10. Cole SPC, Campigotto BMT, Johnson JG, Elliott BE: Differential growth inhibition and enhancement of major histocompatibility complex class I anti8en expression by interferons in a small cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant. Cancer Immunol. Immunother 33: 274-277, 1991.
11. Stam NJ, Kast WM, Woordouw AC, Pastoors LB, Van der Hoeven FA, Melief CJM, Ploegh HL: Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells. J Immunol 142(11): 4113-4117, 1989.
12. Lagadec PF, Saraya KA, Balkwill FR: Human small-cell lung cancer cells are cytokine-resistant but NK/LAR sensitive. Int J Cancer 48(2): 311-317, 1991.
13. Lauzon W, Lemaire I: Effects of biological response modifiers on lung natural killer activity. Immunopharmacology and Immunotoxicology 13(3): 237-250, 1991.
14. Yang SC, Owen-Schaub L, Mendiguren-Rodriguez A, Grimm EA, Hong WK, Roth JA: Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha. J Thorac Cardiovasc Surg 99(1): 8-12, 1990.
15. Johnson EA, Cohen MH, Fosseck BE: Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer 52: 1395-1400, 1983.
16. rd edition, Lippincott 591-705, 1989.